Attribution
Data Sources & Attribution
Ingryd's product information is built on publicly available scientific guidelines and open government data.
Product database
USDA FoodData Central Nutrition data is provided by the U.S. Department of Agriculture (USDA) FoodData Central database, a publicly available resource maintained by a U.S. federal agency. While we strive for accuracy, product formulations may change. Always verify nutrition information by reading the product label. https://fdc.nal.usda.gov
Food scoring systems
Nutri-Score (2023 algorithm) Santé publique France. Nutri-Score — updated algorithm calculation workbook. Ingryd implements the 2023 revision of the front-of-pack nutrition label used across much of Europe.
Fruit, vegetable and legume estimation Vergeer L, et al. (2020). Methodology for the Determination of Fruit, Vegetable, Nut and Legume Points for Products Sold in Canadian Grocery Stores. Foods, 9(8), 1127.
GLP-1 nutrition guidance
Joint advisory — ACLM, ASN, OMA, TOS Mozaffarian D, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 33(8), 1475–1503. DOI 10.1002/oby.24336. This is the source for the protein guidance Ingryd shows. It is also the source for in-app GI and appetite food guidance. It is also the source for the Home sleep context line. It is also the source for the Home water context line. It is also the source for the Home activity context line. It is also the source for the Picks shelves (Easy protein, Fiber, Gentle foods).
Gorgojo-Martínez JJ, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine, 12(1), 145 (published December 2022). DOI 10.3390/jcm12010145. This is the source for in-app guidance on belching. This work was funded by Novo Nordisk.
Wharton S, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine (2022), 134(1), 14–19.
Gentinetta S, et al. Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonists. Diabetes, Metabolic Syndrome and Obesity (2024), 17, 4817–24.
Medication labeling
WEGOVY (semaglutide) injection — Prescribing Information, Medication Guide and Instructions for Use. Novo Nordisk / U.S. Food and Drug Administration, revised February 2026. The source for in-app injection-site guidance when the medication is semaglutide, custom, or not set.
ZEPBOUND (tirzepatide) injection — Prescribing Information and Instructions for Use. Eli Lilly and Company / U.S. Food and Drug Administration, revised September 2025. The source for in-app injection-site guidance when the medication is tirzepatide, and for the estimated medication level.
OZEMPIC (semaglutide) injection — Prescribing Information. Novo Nordisk / U.S. Food and Drug Administration, revised January 2025. MOUNJARO (tirzepatide) injection — Prescribing Information. Eli Lilly and Company, current labeling as of September 2026. TRULICITY (dulaglutide) injection — Prescribing Information. Eli Lilly and Company, revised November 2022. Each label's Clinical Pharmacology section (elimination half-life, absorption, and time to steady state) is the source for the estimated medication level shown on the Next Dose card. That level is a model of what the label describes, computed from your logged shots; it is not a measurement and is not a dosing recommendation.
Dietary fiber
Institute of Medicine Dietary Reference Intakes (DRI) for total fiber: 25 g/day for females under 50, 38 g/day for males under 50, 21 g/day for females 50 and older, and 30 g/day for males 50 and older. These figures are IOM Dietary Reference Intakes, not values from the GLP-1 joint advisory.
This app is not affiliated with, endorsed by, or sponsored by any of the organizations listed above.